Securities code: 000504 securities abbreviation: Nanhua Bio-Medicineco.Ltd(000504) Announcement No.: 2022-015 Nanhua Bio-Medicineco.Ltd(000504)
Reply announcement on the letter of concern of Shenzhen Stock Exchange
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
Nanhua Bio-Medicineco.Ltd(000504) (hereinafter referred to as “the company”) received the attention letter on Nanhua Bio-Medicineco.Ltd(000504) issued by Shenzhen Stock Exchange on February 6, 2022 [company Department attention letter (2022) No. 109] (hereinafter referred to as “the attention letter”), and now replies to the relevant questions are as follows: 1. Supplementary disclosure of the forecast range (or exact number) of operating revenue and operating revenue after deduction in 2021, Explain the recognition and recognition basis of operating revenue in each quarter by business, as well as the specific composition of operating revenue deductions. Company reply: 1. Statement of operating income and operating income after deduction in 2021 (Unaudited)
Description of the project in 2021
The operating income is 161.8378 million yuan
The operating income after deduction is 141.9715 million yuan, and the urban central heating business income is 1986.63 million yuan.
Note: operating income after deduction refers to the operating income after deducting the business income irrelevant to the main business and the income without commercial substance. 2. Quarterly recognition of operating revenue (Unaudited)
Unit: 10000 yuan
Business projects first quarter second quarter third quarter fourth quarter
Energy saving and environmental protection industry:
Sales revenue of energy-saving products 2.78 29.62 2.42 19.96
EMC and engineering construction 233.53 235.70 90.94 263.49
Income from other services in energy conservation industry 103.25 266.09 266.27 499.68
Urban central heating income 1986.63
Subtotal 339.56 531.41 359.63 2769.76
Biomedical industry:
Cell storage and detection income 2444.30 2820.32 3088.21 3114.78
Sales of biomedical related products 529.29 75.25 75.12 36.15
Subtotal 2973.60 2895.57 3163.33 3150.93
Total 3313.15 3426.98 3522.96 5920.69
The company’s main businesses are biomedicine and energy conservation and environmental protection. The biomedicine business covers the production and sales of products such as cell storage and technical services, stem cell therapy research, medical devices and medical consumables, while the energy conservation and environmental protection business mainly includes EMC (contract energy management), energy conservation product sales and engineering project construction Sewage and sludge treatment and other environmental protection extension products.
In terms of revenue recognition, the company’s branches implement the following revenue recognition methods: ① the income from cell storage and custody services belongs to the performance obligation to be performed within a certain period of time. The company provides the client with cross-year human cell activity custody services, and the time progress is recognized as the performance progress, that is, according to the period during which the custody services are provided, The current custody income of the service year shall be determined by stages according to the contract or agreement price received or receivable from the labor recipient; ② The income from cell testing services belongs to the performance obligation to be performed at a certain point in time. The company accepts the entrustment to provide testing and other labor services for human derived cells. After completing the procedures of cell separation, freezing and testing, the company will provide human derived cells that meet the storage conditions of receiving cell activity, After notifying the customer of the qualified test results, the company uploads the report to the system, and recognizes the test labor revenue at one time according to the contract or agreement price received or receivable from the labor recipient; ③ EMC (contract energy management) and BT (construction transfer) revenue belong to the performance obligations to be performed within a certain period of time. For providing BT to participate in public infrastructure construction business, the company determines the performance progress of providing construction business according to the output method, and recognizes the revenue according to the performance progress; For EMC business, the company confirms the performance progress of services provided according to the monthly energy saving, and confirms the revenue according to the performance progress; ④ The company’s revenue from selling goods belongs to the performance obligation to be performed at a certain point in time. The company has delivered the products to the buyer according to the contract and confirmed by the customer. The revenue is recognized when the amount of product sales revenue has been determined, the payment for goods has been recovered or the collection voucher has been obtained, and the relevant economic benefits are likely to flow in, and the cost related to the products can be measured reliably; ⑤ The income from urban central heating belongs to the performance obligation to be performed within a certain period of time. The company allocates and recognizes the income according to the heat fee received in a heating season. 3. Deduction form of operating income in 2021 (Unaudited)
Description of business income before deduction and after deduction
Input amount (10000 yuan) (10000 yuan) input amount (10000 yuan)
Energy conservation and environmental protection business:
Sales revenue of energy-saving products 54.78
EMC and engineering construction 823.66 823.66
Income from other services in energy-saving industry 1135.29
Full deduction of income: including heat supply income, urban central heating income of 1986.63 million yuan, 19.4067 million yuan Deduct 459600 yuan of coal sales revenue.
Subtotal 4000.36 1986.63 2013.73
Biomedical business:
Income from cell storage and detection 11467.61
Sales of biomedical related products 715.81 715.81
Subtotal 12183.42 11480.83
Total 16183.78 1986.63 14197.15
2、 With reference to the specific deduction items listed in “4.2 matters related to business income deduction” in the “guidelines for self regulation and supervision of listed companies No. 1 – business handling” of the exchange, explain in detail whether your company has completely deducted the business income irrelevant to the main business and the income without commercial substance, and whether it has pre communicated with the annual audit accountant on the deduction of business income. Company reply:
The company compares and analyzes the business income data in recent years, With reference to the provisions of “4.2 matters related to deduction of operating income” in the guidelines for self discipline supervision of listed companies of Shenzhen Stock Exchange No. 1 – business handling: “Business income irrelevant to the main business refers to all kinds of income not directly related to the normal business operation of the listed company, or related to the normal business operation of the listed company, but due to its special nature, contingency and temporary nature, it affects the users of the statement to make a normal judgment on the sustainable operation ability of the company.” The company deducted the urban central heating business income of RMB 1986.63 million in full during the reporting period. The main reasons for the deduction are: the urban central heating business is Chengguang energy conservation, the holding subsidiary of the company. According to the housing and Urban Rural Development Bureau of Minxian County, where the business is located It was carried out on the basis of the reply document on “collection of temporary heating fee” given by Minxian development and Reform Bureau on September 30, 2021. In view of the fact that the business is a new business in 2021 and there is uncertainty about its sustainability in the future, the company carefully deducted the full amount of income. See “I and 3” of this reply for the details of deduction. The deduction of the company’s operating income does not have the deductible items required by the guidelines for self discipline supervision of listed companies of Shenzhen Stock Exchange No. 1 – business handling.
The company has made pre communication with the annual audit accountant on the deduction of operating income, and there is no difference between the two sides.
3、 On January 1, 2022, your company disclosed the announcement on obtaining interest exemption and related party transactions. Hunan Caixin Financial Holding Group Co., Ltd., the indirect controlling shareholder of the company, exempted the interest payable by the company from April 1 to December 31, 2021, totaling RMB 9.1978 million. Please explain in detail whether the above loan interest exemption has fulfilled the necessary approval procedures of state-owned assets and superior competent departments, whether the relevant approval procedures have been completed in 2021, whether there are other agreements or transaction arrangements at the same time, and whether the relevant profits and losses can be included in 2021. Company reply:
1. At the end of November 2021, the company applied to the major shareholder Hunan Caixin Industry Fund Management Co., Ltd. (hereinafter referred to as “Caixin industry fund”) for instructions on granting exemption support for loan interest of RMB 9.1978 million; Caixin industrial fund then submitted an application to its parent company, namely Nanhua Bio-Medicineco.Ltd(000504) company creditor’s right company – Hunan Caixin Financial Holding Group Co., Ltd. (hereinafter referred to as “Caixin financial holding”). On December 3, 2021, the board of directors of Caixin financial holding agreed to exempt the company from the above related interest (this matter does not need the approval of its superior competent unit, Hunan Provincial Department of Finance). So far, the matter has fulfilled the necessary approval procedures.
2. The company received the letter on Exemption of Nanhua Bio-Medicineco.Ltd(000504) related interest from Caixin financial holding on December 21, 2021. In order to support the sustainable and steady development of the company and implement the spirit of relevant documents, Caixin financial holding decided to exempt the total interest payable by the company from April 1 to December 31, 2021 of RMB 9.1978 million.
The company held the first meeting of the 11th board of directors on December 31, 2021. The meeting deliberated and approved the proposal on obtaining interest exemption and related party transactions, and agreed that the company would accept the total interest payable by Caixin Financial Holdings, the investor of Caixin industry fund, the controlling shareholder of the company, from April 1 to December 31, 2021
The total is 9.1978 million yuan.
There is no other agreement or transaction arrangement for the above interest exemption.
3. To sum up, this interest exemption has fulfilled the relevant approval procedures in 2021; company
According to the relevant provisions of the accounting standards for business enterprises, this interest exemption is regarded as an equity transaction, and the exempted interest will be paid
The amount of 9.1978 million yuan is included in 2021 as capital reserve, increasing the company’s net assets in 2021.
4、 Itemize the estimated impairment amount and impairment reasons of various assets of your company in 2021, and combine them with your company
The company’s business development, detailing whether the estimated impairment amount of each asset is sufficient.
Company reply:
1. The impairment losses of various assets accrued by the company at the end of 2021 are as follows:
(1) Accounts receivable unit: Yuan
Closing balance bad debt provision for the current period opening bad debt provision combination name book balance bad debt provision provision proportion reserve amount balance
(%)
Aging combination 227354086.37 11033427.92 4.85
